HuGE Literature Finder
Records 1-30
|
Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.
Scientific reports 2021 Jan 11 (1): 415. Sanchez-Spitman A B, Swen J J, Dezentjé V O, Moes D J A R, Gelderblom H, Guchelaar H |
|
Model-based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Clinical pharmacology and therapeutics 2020 Oct . Puszkiel Alicja, Arellano Cécile, Vachoux Christelle, Evrard Alexandre, Le Morvan Valérie, Boyer Jean-Christophe, Robert Jacques, Delmas Caroline, Dalenc Florence, Debled Marc, Venat-Bouvet Laurence, Jacot William, Dohollou Nadine, Bernard-Marty Chantal, Laharie-Mineur Hortense, Filleron Thomas, Roché Henri, Chatelut Etienne, Thomas Fabienne, White-Koning Melan |
|
ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Progress in neuro-psychopharmacology & biological psychiatry 2020 Jul 110042. Ganoci Lana, Trkulja Vladimir, Živkovic Maja, Božina Tamara, Šagud Marina, Lovric Mila, Božina Na |
|
Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
British journal of clinical pharmacology 2020 Jul . Thorén Linda, Lindh Jonatan D, Ackehed Gerd, Kringen Marianne Kristiansen, Hall Per, Bergh Jonas, Molden Espen, Margolin Sara, Eliasson Er |
|
Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant).
Medicine 2020 Feb 99 (8): e19083. Chan Carmen Wing Han, Miaskowski Christine, McCarthy Alexandra, Waye Mary Miu Yee, Yeo Winnie, So Winnie Kwok Wai, Choi Kai Chow, Tsui Stephen Kwok Wing, Chan Judy Yuet |
|
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Clinical and translational science 2019 Oct . Nardin Jeanine Marie, Schroth Werner, Almeida Thais Abreu, Mürdter Thomas, Picolotto Solane, Vendramini Evelyn Castillo Lima, Hoppe Reiner, Kogin Jenifer Primon, Miqueleto Diandra, de Moraes Silvia Dark Robaskievicz, Schwab Matthias, Pecoits-Filho Roberto Flavio, Brauch Hiltrud, Casali-da-Rocha José Claud |
|
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
Clinical drug investigation 2019 Sep . Wei Xiaoxia, Sun Hong, Zhuang Jie, Weng Xiuhua, Zheng Bin, Lin Qiwang, Zhang Guifeng, Cai Jiaq |
|
Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol.
Toxicology and applied pharmacology 2019 Jun 114619. Chao Ta-Chung, Pan Wen-Chi, Tsai Yi-Fang, Chou Yueh-Ching, Liu Yu-Rong, Wang Sheng-Fan, Chen Ying-Jen, Soucek Pavel, Ueng Yune-Fa |
|
Factors affecting tamoxifen metabolism in breast cancer patients; preliminary results of the French PHACS study (NCT01127295).
Clinical pharmacology and therapeutics 2019 Feb . Puszkiel Alicja, Arellano Cécile, Vachoux Christelle, Evrard Alexandre, Le Morvan Valérie, Boyer Jean-Christophe, Robert Jacques, Delmas Caroline, Dalenc Florence, Debled Marc, Venat-Bouvet Laurence, Jacot William, Suc Etienne, Sillet Bach Isabelle, Filleron Thomas, Roché Henri, Chatelut Etienne, White-Koning Melanie, Thomas Fabien |
|
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
Breast cancer (Tokyo, Japan) 2019 Feb . Ishiguro Hiroshi, Ohno Shinji, Yamamoto Yutaka, Takao Shintaro, Sato Nobuaki, Fujisawa Tomomi, Kadoya Takayuki, Kuroi Katsumasa, Bando Hiroko, Teramura Yasufumi, Iwata Hiroji, Tanaka Shiro, Toi Masaka |
|
Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis.
Cancer chemotherapy and pharmacology 2019 Jan 83 (1): 71-79. Bai Yu, Wu Hai-Wei, Zhang Yan-H |
|
CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen.
Biomedical reports 2018 Nov 9 (5): 446-452. Saghafi Fatemeh, Salehifar Ebrahim, Janbabai Ghasem, Zaboli Ehsan, Hedayatizadeh-Omran Akbar, Amjadi Omolbanin, Moradi Siava |
|
Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
Breast cancer research and treatment 2018 Aug . Sanchez-Spitman A B, Dezentjé V O, Swen J J, Moes D J A R, Gelderblom H, Guchelaar Henk-J |
|
Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
Pharmacogenomics 2018 Jul . Sim Sarah, Lövrot John, Lindh Jonatan D, Bergh Jonas, Xie Hanji |
|
Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10 T/T genotype breast cancer patients in China.
International journal of cancer 2018 Jul . Lan Bo, Ma Fei, Chen Shanshan, Wang Wenna, Li Qiao, Fan Ying, Luo Yang, Cai Ruigang, Wang Jiayu, Yuan Peng, Zhang Pin, Li Qing, Xu Bing |
|
Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy
Asian Pacific journal of cancer prevention : APJCP 2018 Feb 19 (2): 343-350. Thota Kanakaiah, Prasad K, Basaveswara Rao Mandava |
|
Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?
Clinical pharmacology and therapeutics 2018 04 103 (4): 653-662. Cajanus Kristiina, Neuvonen Mikko, Koskela Outi, Kaunisto Mari A, Neuvonen Pertti J, Niemi Mikko, Kalso Ei |
|
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Breast cancer research : BCR 2018 12 20 (1): 149. Brooks Jennifer D, Comen Elizabeth A, Reiner Anne S, Orlow Irene, Leong Siok F, Liang Xiaolin, Mellemkjær Lene, Knight Julia A, Lynch Charles F, John Esther M, Bernstein Leslie, Woods Meghan, Doody David R, , Malone Kathleen E, Bernstein Jonine |
|
Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.
The pharmacogenomics journal 2018 04 18 (2): 201-208. Hwang G S, Bhat R, Crutchley R D, Trivedi M |
|
Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.
Advances in pharmacology (San Diego, Calif.) 2018 83 65-91. Cronin-Fenton Deirdre P, Damkier P |
|
The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
International journal of cancer 2018 07 143 (1): 184-189. Lan Bo, Ma Fei, Zhai Xiaoyu, Li Qiao, Chen Shanshan, Wang Jiayu, Fan Ying, Luo Yang, Cai Ruigang, Yuan Peng, Zhang Pin, Li Qing, Xu Bing |
|
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
Breast cancer research and treatment 2017 Nov 166 (1): 277-287. Hertz D L, Kidwell K M, Hilsenbeck S G, Oesterreich S, Osborne C K, Philips S, Chenault C, Hartmaier R J, Skaar T C, Sikora M J, Rae J |
|
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
Breast cancer research : BCR 2017 Nov 19 (1): 125. Helland Thomas, Henne Nina, Bifulco Ersilia, Naume Bjørn, Borgen Elin, Kristensen Vessela N, Kvaløy Jan T, Lash Timothy L, Alnæs Grethe I G, van Schaik Ron H, Janssen Emiel A M, Hustad Steinar, Lien Ernst A, Mellgren Gunnar, Søiland Håva |
|
CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.
Scientific reports 2017 Aug 7 (1): 7727. Damkier Per, Kjærsgaard Anders, Barker Kimberly A, Cronin-Fenton Deidre, Crawford Anatasha, Hellberg Ylva, Janssen Emilius A M, Langefeld Carl, Ahern Thomas P, Lash Timothy |
|
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aug JCO2017733246. Goetz Matthew P, Suman Vera J, Reid Joel M, Northfelt Don W, Mahr Michael A, Ralya Andrew T, Kuffel Mary, Buhrow Sarah A, Safgren Stephanie L, McGovern Renee M, Black John, Dockter Travis, Haddad Tufia, Erlichman Charles, Adjei Alex A, Visscher Dan, Chalmers Zachary R, Frampton Garrett, Kipp Benjamin R, Liu Minetta C, Hawse John R, Doroshow James H, Collins Jerry M, Streicher Howard, Ames Matthew M, Ingle James |
|
The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer.
Pakistan journal of pharmaceutical sciences 2017 May 30 (3(Special)): 1095-1098. Zeng Yi, Huang Kai, Huang Weiw |
|
Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.
Frontiers in pharmacology 2017 8 582. Schroth Werner, Winter Stefan, Mürdter Thomas, Schaeffeler Elke, Eccles Diana, Eccles Bryony, Chowbay Balram, Khor Chiea C, Tfayli Arafat, Zgheib Nathalie K, Eichelbaum Michel, Schwab Matthias, Brauch Hiltr |
|
The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis.
OncoTargets and therapy 2017 10 5429-5437. Lu Junjun, Li He, Guo Peng, Shen Rui, Luo Yingbin, Ge Qiao, Shi Wenfei, Li Yan, Zhu Weika |
|
Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology 0 22 (5): 1217-1226. Argalacsova Sona, Slanar Ondrej, Bakhouche Hana, Pertuzelka Lub |
|
Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen.
European journal of gynaecological oncology 0 37 (5): 700-702. de Vasconcelos-Valenca R J, Melo M A, Lima E, de Sousa G V, Nazario A C, da Siilva B |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: